Cellectar Biosciences (CLRB) Total Current Liabilities (2010 - 2026)

Cellectar Biosciences has reported Total Current Liabilities for 16 years, with the latest figure at $4.7 million in Q4 2025.

• Quarterly Total Current Liabilities fell 49.4% year-over-year to $4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.7 million (down 49.4% YoY) and the FY2025 annual result came in at $4.7 million, down 49.4% from the prior year.
• Total Current Liabilities fell to $4.7 million in Q4 2025 per CLRB's latest filing, from $4.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $29.8 million in Q3 2023 and troughed at $3.2 million in Q3 2021.
• A 5-year average of $11.1 million and a median of $7.2 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 319.33% in 2023, then tumbled 78.91% in 2025.
• Over 5 years, Total Current Liabilities stood at $4.0 million in 2021, then soared by 188.23% to $11.5 million in 2022, then surged by 120.48% to $25.4 million in 2023, then slumped by 62.98% to $9.4 million in 2024, then slumped by 49.4% to $4.7 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $4.7 million, $4.9 million, and $5.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.